I would say those folks are I'll informed. HGEN was pretty much in the same boat as us. They got a nice cash infusion from a partner so all they needed to do was a reverse split to qualify for the price stipulation. They did that and were uplisted. Their trial is still ongoing, they have no revenue or approved drug to sell. Same as us except all criteria met for nasdaq. CYDY just has to check all the boxes like everyone else. Nothing more. They have already said the nasdaq has not rejected their application, so it's not expired and they are still communicating. That's my take anyway.